Pediatric vaccination rates for certain diseases have been declining in recent years, contributing to risk for outbreaks of certain infectious diseases. Speak to your doctor to learn more about how to detect and help prevent many infectious diseases.

We’re excited to share new data from our neuroscience pipeline at #CTAD25, including results for two #AlzheimersDisease candidates. The U.S. FDA has granted Fast Track Designation to one of our candidates for the treatment of Alzheimer's. Learn more: https://t.co/gLNUamriR6

We’re presenting important new research from our expanding #hematology pipeline at #ASH25. Learn more about the novel approaches we’re exploring for patients with hematologic neoplasms and malignancies: https://t.co/or9E1gcIN9

Together with @pfizer and @AstellasUS, we’re proud to announce the #FDA approval of two new treatment combinations for certain patients with muscle-invasive #BladderCancer (MIBC). Learn more: https://t.co/RlPqQD3UiX

We are excited to announce positive topline Phase 3 results for our investigational oral #HIV treatment in treatment-naïve adults with HIV-1 infection: https://t.co/qypFDXe2fJ

We’re proud to announce the European Commission has approved a new route of administration for a treatment option for patients with certain types of #cancer in the EU. Learn more here: https://t.co/Z5sz0KVWVN

We’re pleased to announce topline results from our Phase 2 study in a type of pulmonary hypertension (#PH). Learn more here: https://t.co/9UkwB6yjFL

Today, we announced an agreement to acquire Cidara Therapeutics, Inc., diversifying our respiratory portfolio to include an investigational long-acting strain-agnostic antiviral agent being evaluated for the prevention of influenza in individuals at higher risk of complications.

We’re pleased to share new Phase 3 data for our investigational treatment in adults with heterozygous familial hypercholesterolemia, an inherited type of high LDL-cholesterol. Learn more: https://t.co/hzElzPBT0i

Today at #AHA25, we shared first-time Phase 3 results of our investigational oral macrocyclic peptide. Learn more: https://t.co/8NmLpLuA8D

Today, we announced a strategic funding agreement with Blackstone, positioning our company to advance development of an investigational antibody-drug conjugate targeting TROP2 while we continue to advance our broad and expansive pipeline. Read more: https://t.co/JVr8YSppPV

Join us today at 9 a.m. ET to learn more about our Q3 2025 #earnings: https://t.co/Ng3iAWzV46 $MRK

Our Q3 2025 #earnings results are live. Check out our full $MRK financial summary and key highlights: https://t.co/nhnLWMogA8

Learn more about our latest update in #oncology here: https://t.co/Vh7pSR3Xae

Today, we announced the European Commission’s approval of a new treatment option for certain patients with head and neck squamous cell carcinoma. Read more here: https://t.co/VBSrx8RChd

Today we announced positive topline Phase 3 trial results evaluating a combination regimen in #kidneycancer as we continue to work toward new treatment options for patients with renal cell carcinoma #RCC. https://t.co/h8b0ntRVBm

Today we announced positive topline results for our Phase 3 trial in advanced #kidneycancer in collaboration with @EisaiUS, reinforcing our commitment for patients with renal cell carcinoma #RCC. https://t.co/CMKVsmwxav

We’re proud to announce the #FDA approval of a label update for a treatment option for patients with pulmonary arterial hypertension (#PAH). Learn more here: https://t.co/AaBFVP4oik

The FDA has granted priority review for our immunotherapy regimens for certain patients with muscle-invasive #BladderCancer (MIBC). Currently, almost half of people with MIBC have few options other than surgery. https://t.co/Cqeb76nt7j

We’re presenting new data across our cardio-pulmonary portfolio and pipeline to help in the fight against the CV epidemic at #AHA25. Learn more here: https://t.co/N5zU0VBNpe